Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.64 USD | -0.06% | +6.47% | -6.77% |
05:47pm | HC Wainwright Adjusts Catalyst Pharmaceuticals' Price Target to $26 From $24, Keeps Buy Rating | MT |
05-09 | Transcript : Catalyst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.77% | 1.85B | |
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-14.05% | 32.43B | |
+55.89% | 24.28B | |
-15.95% | 15.52B | |
-41.29% | 12.17B | |
-15.35% | 12.01B | |
-11.75% | 12B | |
+7.87% | 8.87B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals